Navigation Links
Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
Date:5/3/2012

HAYWARD, Calif., May 3, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended March 31, 2012.

Financial Results:

Total operating expenses for the first quarter ended March 31, 2012 were $20.1 million, as compared to $28.4 million for the fourth quarter ended December 31, 2011. The decrease in operating expenses can be primarily attributed to the completion of enrollment of the PEARL-SC study in the fourth quarter. The Company expects operating expenses to decline further in subsequent quarters following the discontinuation of varespladib development.

Anthera ended the first quarter of 2012 with approximately $44.0 million in cash and cash equivalents and short-term investments.  This is compared to $67.4 million in cash and cash equivalents and short-term investments for the fourth quarter ended December 31, 2011. The Company expects cash burn for the second quarter ended June 30, 2012 to be approximately $13.0-15.0 million.

Anthera will host a conference call at 8:30 a.m. Eastern Time tomorrow, May 4, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 76225935. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 76225935.  The audio replay will be available until May 11, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • The PEARL-SC Data Safety Monitoring Board (DSMB) met for the fourth time to review available safety data and recommended the study continue without change. The PEARL-SC study is examining the therapeutic benefit of monthly and weekly subcutaneous doses of blisibimod in p
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
    (Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
    (Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
    Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
    ... ANNAPOLIS, Md., Oct. 13, 2011 PharmAthene, Inc. (NYSE Amex: ... its legal brief in response to SIGA Technologies, motion for ... Court of Chancery had issued a ruling in its litigation ... over 10 years from all sales of ST-246 and related ...
    ... 13, 2011 A Medco Health Solutions, Inc. (NYSE: ... 38 percent of patients prescribed Plavix® (clopidogrel)—an anti-platelet drug ... also using another drug that would impede its effectiveness. ... analysis also showed that primary care physicians seem willing ...
    Cached Medicine Technology:PharmAthene Submits Legal Brief in Response to SIGA Technologies' Motion for Reargument 2PharmAthene Submits Legal Brief in Response to SIGA Technologies' Motion for Reargument 3Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 2Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 3Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 4
    (Date:8/30/2014)... Colorado Springs, CO (PRWEB) August 30, 2014 ... valuable, and increasingly difficult to get. Snoring and sleep apnea ... breathing stops) rob people and their bed partners of the ... Up to 45% of the population snores and 20 million ... these, only 10% have been diagnosed and treated; and of ...
    (Date:8/30/2014)... "My wife suffered neck, back and ... said one of two inventors from Bethel, Alaska. "The ... and neck area. She tried other pillows to little ... assisting in comfort and providing extra sleep." , They ... support the head, neck and back comfortably. This enables ...
    (Date:8/30/2014)... (PRWEB) August 30, 2014 Market ... Industry, 2009-2019 is a professional and in-depth market ... The report firstly reviews the basic information of ... technology. The report then explores global and China’s ... specification, capacity, production value, and market share etc. ...
    (Date:8/30/2014)... 30, 2014 Serving contented clients since ... Profit By Outsourcing is now offering discount for ... company gives emphasize on putting forward the best of ... clients. Their dedicated team of professionals and web developers ... can handle even the critical issues of web development ...
    (Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
    Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3
    ... firm announced this week that it has developed a ... improve// the efficacy of chemotherapy drugs and reduce drug ... the US subsidiary of Nitto Denko Corporation, says its ... biocompatible polymer material which can be loaded with therapeutic ...
    ... study appearing in the Journal of Clinical Oncology reveals ... the lives of patients// with recurrent prostate cancer. ... targeted drugs that scientists at Cedars-Sinai Medical Center in ... in some prostate cancer patients with no previous chemotherapy ...
    ... of the Medgadget "Most Sci-Fi Sounding Company Name" Award, ... Andara OFS nerve growth stimulation system. ,According ... battery-powered device about the size of a cardiac pacemaker ... attached to the vertebrae at a distance of two ...
    ... have cautioned about the risk of mercury in canned albacore ... regarding the consumption of tuna in women and children. This ... 8 out of 60 cans of albacore tuna tested contained ... this guideline, four servings of canned albacore tuna per week ...
    ... A research team has identified certain chemical marks that help ... cells in liposuctioned fat, are best at regenerating// tissue. ... body fat to improve their looks. But unwanted fat also ... heal injuries in the body. ,Uncovering the nature ...
    ... Medicine have succeeded in producing neurons in vitro ... This is the first time// such an advanced ... from human skin, according to lead researcher Professor ... revolutionary advances in the treatment of neurodegenerative illnesses ...
    Cached Medicine News:Health News:New Cost-cutting Cancer Drug Delivery System 2Health News:New Cost-cutting Cancer Drug Delivery System 3Health News:Stem Cells in Liposuctioned Fat can Heal Injuries 2Health News:Scientists Produce Neurons from Human Skin 2